ONCOLYTIC VIRUS

Embodiments of the present disclosure concern oncolytic viruses, such as vaccinia virus, for example, for the treatment of cancer, wherein the viruses encode an engager molecule having an activation domain that recognizes a cell molecule, such as CD3, for example, on T cells and an antigen recognition domain that recognizes a tumor antigen, such as EphA2, HER2, GD2, or Glypican-3, for example. In some embodiments, the engager molecules further comprise a cytokine or co-stimulatory domain, for example. Methods of treating cancer using one or more of the compositions are encompassed in the disclosure. 1. An oncolytic virus that encodes a bipartite molecule comprising a single chain variable fragment (scFv) specific for a cell surface molecule and a scFv specific for a tumor antigen.2. The virus of claim 1 , wherein the cell surface molecule is on effector cells.3. The virus of claim 2 , wherein the effector cells are T lymphocytes.4. The virus of claim 1 , wherein the tumor antigen is selected from the group consisting of EphA2 claim 1 , HER2 claim 1 , or GD2.5. The virus of claim 1 , wherein the cell surface molecule is selected from the group consisting of CD3 claim 1 , CD4 claim 1 , CD5 claim 1 , CD8 claim 1 , CD16 claim 1 , CD28 claim 1 , CD40 claim 1 , CD134 claim 1 , CD137 claim 1 , and NKG2D.6. The virus of claim 1 , wherein the cell surface molecule is CD3.7. The virus of claim 1 , wherein the oncolytic virus is vaccinia virus claim 1 , adenovirus claim 1 , Herpes simplex virus 1 (HSV1) claim 1 , myxoma virus claim 1 , reovirus claim 1 , poliovirus claim 1 , vesicular stomatitis virus (VSV) claim 1 , measles virus (MV) claim 1 , or Newcastle disease virus (NDV).8. A method of treating an individual for cancer claim 1 , comprising the step of delivering to the individual a therapeutically effective amount of the virus of .9. The method of claim 8 , wherein the amount of the virus comprises 10-10pfu of the virus.10. The method of claim 8 , further comprising the ...

Engager cells for immunotherapy

Embodiments concern methods and/or compositions related to immunotherapy for cancer. In particular embodiments, engager immune cells harbor a vector that encodes a secretable engager molecule. In particular cases, the engager molecule has an activation domain and an antigen recognition domain. In some embodiments, the engager molecules further comprise a cytokine or co-stimulatory domain, for example.

VASCULAR-TARGETED T-CELL THERAPY

Embodiments of the invention provide for cell therapy for cancers having a TEM1 or TEM8 antigen. Certain embodiments provide for cell therapy that targets tumor vasculature, including the tumor vascular bed, for example. In specific embodiments, TEM1- and/or TEM8-specific chimeric antigen receptors are employed. 1. A polynucleotide comprising sequence that encodes a TEM1-specific chimeric antigen receptor.2. A polynucleotide comprising sequence that encodes a TEM8-specific chimeric antigen receptor.3. The polynucleotide of claim 1 , further comprising sequence that encodes a TEM8-specific chimeric antigen receptor.4. The polynucleotide of or claim 1 , wherein the chimeric antigen receptor comprises a transmembrane domain selected from the group consisting of CD3-zeta and CD28.5. The polynucleotide of or claim 1 , wherein the chimeric antigen receptor comprises co-stimulatory molecule endodomains selected from the group consisting of CD28 claim 1 , CD27 claim 1 , 4-1BB claim 1 , OX40 ICOS claim 1 , and a combination thereof.65. An expression vector comprising the polynucleotide of any one of through .7. The vector of claim 6 , wherein the vector is a viral vector.8. The vector of claim 7 , wherein the viral vector is a retroviral vector claim 7 , lentiviral vector claim 7 , adenoviral vector claim 7 , or adeno-associated viral vector.98. A cell claims 6 , comprising the expression vector of any one of through .10. The cell of claim 9 , wherein said cell is a eukaryotic cell.11. The cell of claim 9 , wherein the cell is an immune system cell.12. The cell of claim 9 , wherein the cell is a T cell claim 9 , NK cell claim 9 , or NKT cell.1312. A method of treating an individual for cancer claims 9 , comprising the step of providing a therapeutically effective amount of a plurality of any of cells of -.14. The method of claim 13 , wherein the cancer is a solid tumor.15. The method of claim 13 , wherein the cancer comprises solid tumors that are about 2 mm or greater in ...

ENGAGER CELLS FOR IMMUNOTHERAPY

Embodiments concern methods and/or compositions related to immunotherapy for cancer. In particular embodiments, engager immune cells harbor a vector that encodes a secretable engager molecule. In particular cases, the engager molecule has an activation domain and an antigen recognition domain. In some embodiments, the engager molecules further comprise a cytokine or co-stimulatory domain, for example. 1. A cell comprising a polynucleotide vector encoding a bipartite molecule comprising an activation domain that binds to one or more cell surface molecules and an antigen recognition domain that binds to EphA2 and/or CD19.2. The cell of claim 1 , wherein the activation domain claim 1 , antigen recognition domain claim 1 , or both domains comprise single chain fragment variable (scFV) antibody moieties.3. The cell of claim 1 , wherein the activation domain is a scFV that recognizes a molecule selected from the group consisting of CD3 claim 1 , CD16 claim 1 , CD27 claim 1 , CD28 claim 1 , CD40 claim 1 , CD134 claim 1 , and CD137.4. The cell of claim 1 , wherein the vector is a non-viral or viral vector.5. The cell of claim 4 , wherein the viral vector is selected from the group consisting of lentiviral claim 4 , adenoviral claim 4 , retroviral claim 4 , and adeno-associated viral vector.6. The cell of claim 1 , wherein the vector is an oncolytic vector.7. A method of treating an individual with cancer claim 1 , comprising the step of delivering a therapeutically effective amount of one or more cells of to the individual.8. The method of claim 7 , wherein the cancer is EphA2-positive or CD19-positive.9. The method of claim 7 , wherein the vector is selected from the group consisting of lentiviral claim 7 , adenoviral claim 7 , retroviral claim 7 , and adeno-associated viral vector.10. The method of claim 7 , wherein the individual is provided with an additional cancer therapy.11. The method of claim 10 , wherein the additional cancer therapy is surgery claim 10 , ...

Engager cells for immunotherapy

Embodiments concern methods and/or compositions related to immunotherapy for cancer. In particular embodiments, engager immune cells harbor a vector that encodes a secretable engager molecule. In particular cases, the engager molecule has an activation domain and an antigen recognition domain. In some embodiments, the engager molecules further comprise a cytokine or co-stimulatory domain, for example.

用於免疫治療的銜接器細胞